ANI Pharmaceuticals Inc
NASDAQ:ANIP
ANI Pharmaceuticals Inc
Free Cash Flow
ANI Pharmaceuticals Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP
|
Free Cash Flow
$47.8m
|
CAGR 3-Years
298%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Free Cash Flow
$19.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Free Cash Flow
$13.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
|
Pfizer Inc
NYSE:PFE
|
Free Cash Flow
$8.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Free Cash Flow
$14.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Free Cash Flow
$414.3m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-17%
|
|
ANI Pharmaceuticals Inc
Glance View
ANI Pharmaceuticals Inc. operates at the heart of the pharmaceutical industry with a focused strategy that blends generics with niche high-value medications. Born in the realm of specialty pharmaceuticals, the company has crafted a business model that leverages both organic growth and strategic acquisitions. This dual approach helps the company to broaden its product offerings and maintain a robust pipeline. By targeting niche markets often overlooked by larger pharmaceutical giants, ANI maximizes its opportunities in areas with less competitive congestion. Central to its operations is the manufacturing and marketing of generic prescription products that are not only critically required but also pose less risk of commoditization due to their complexity, regulatory hurdles, or limited manufacturing capabilities. Revenue generation for ANI is a sophisticated blend of manufacturing, marketing, and brand positioning. The company's infrastructure supports integrated product development, regulatory approval, and scalable manufacturing processes. This allows them to efficiently bring to market a diverse portfolio of more than a hundred products across therapeutic areas. Additionally, ANI taps into revenue streams by producing legacy branded drugs often acquired from larger players looking to offload non-core assets. These legacy products, while sometimes in smaller volumes, benefit from loyal prescriber bases and established market presence, providing a steady income for the company. In essence, ANI Pharmaceuticals thrives on navigating the intricacies of the pharmaceutical supply chain, seizing opportunities in underexplored niches and refocusing the potential of undervalued brands.
See Also
What is ANI Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
47.8m
USD
Based on the financial report for Dec 31, 2024, ANI Pharmaceuticals Inc's Free Cash Flow amounts to 47.8m USD.
What is ANI Pharmaceuticals Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
9%
Over the last year, the Free Cash Flow growth was -57%. The average annual Free Cash Flow growth rates for ANI Pharmaceuticals Inc have been 298% over the past three years , 4% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet